Brought to you by 
BioXell grosses €17mm with Series B round
04 Sep 2012
Executive Summary
Biotech immunology company BioXell SPA (spun off from Roche in March 2002) has grossed €17mm ($19.9mm) in its Series B financing. NIB Capital Private led the round and was joined by existing investors MPM Capital, Index Ventures, and Life Sciences Partners, plus new investor Investimenti Piccole.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Financing
- Venture Financing
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com